Alex Zhavoronkov, PhD — Comprehensive Profile

Compiled: 2026-04-29. Sources: Wikipedia, Forbes, Insilico Medicine, Google Scholar, PubMed, media archives.

1. Executive Bio

Alex Zhavoronkov (born Aleksandrs Zavoronkovs in Riga, Latvia) is the founder and CEO of Insilico Medicine (HKEX: 2257.HK — listed December 2025), a clinical-stage biotechnology company pioneering the use of generative artificial intelligence for end-to-end drug discovery and development. He is one of the most visible and prolific figures at the intersection of AI, drug discovery, and longevity / aging research.

Zhavoronkov holds two bachelor's degrees from Queen's University at Kingston (Canada), a master's in biotechnology from Johns Hopkins University, and a PhD in physics and mathematics from Moscow State University. Before moving into biotechnology, he worked in graphics processing (at ATI Technologies / NVIDIA-era GPU computing), an unusual pedigree that informed his later application of GPU-accelerated deep learning to pharmacology. He has held or holds adjunct positions at the Moscow Institute of Physics and Technology and, as of 2024, at the Buck Institute for Research on Aging. He is also the director of the UK-based Biogerontology Research Foundation.

He founded Insilico Medicine in 2014 at Johns Hopkins University's incubator in Baltimore, with a thesis that massive biomedical datasets combined with deep learning could radically compress the time and cost of drug discovery. Early investors included Tony Robbins and Peter Diamandis. Under his leadership Insilico pioneered the use of generative adversarial networks (GANs) for molecular design (2016–2018), published the landmark GENTRL paper in Nature Biotechnology (2019) demonstrating the first AI-designed DDR1 kinase inhibitor generated in 21 days, and built commercial platforms PandaOmics (target discovery), Chemistry42 (generative chemistry), and InClinico (clinical-trial outcome prediction).

In 2021 Insilico's lead program ISM001-055 / rentosertib — a TNIK inhibitor for idiopathic pulmonary fibrosis (IPF) — became the first drug with both an AI-discovered target and an AI-generated molecule to enter human clinical trials. In 2023 it entered Phase II trials. In 2025 the **Phase IIa results were published in Nature Medicine, establishing rentosertib as the first end-to-end generative-AI–designed drug with positive human efficacy data. Insilico IPO'd on the Hong Kong Stock Exchange in December 2025**. The company has partnerships with ~10 of the top 20 global pharma companies, including Sanofi, Exelixis, Fosun, and Menarini.

Zhavoronkov is a Forbes contributor (200+ articles since 2018), author of the 2013 book The Ageless Generation, co-editor of Springer's Artificial Intelligence for Healthy Longevity (2023), and has authored or co-authored 250+ peer-reviewed publications (PubMed-indexed) with >20,000 Google Scholar citations. He is a frequent keynote speaker at JPMorgan Healthcare Conference, NVIDIA GTC, ARDD (Aging Research & Drug Discovery) Copenhagen, the Longevity Forum, and the World Economic Forum.

2. Career Timeline

3. Insilico Medicine — Milestones

• 2014 — Incorporated at Johns Hopkins University, Baltimore
• 2015–2016 — Publishes foundational deep-learning-in-biomedicine papers; builds Aging.AI clock
• 2016 — druGAN (first use of adversarial autoencoders to generate molecules with desired properties, Mol. Pharm.)
• 2017 — ORGAN/ORGANIC (objective-reinforced generative adversarial networks for molecular design)
• 2018 — Adversarial Autoencoders for compound generation with specified anticancer properties
• 2019 — GENTRL: Reinforcement-learning generative tensorial model designs DDR1 kinase inhibitor in 21 days; Nature Biotechnology paper; lead compound validated in vivo in mice (landmark in generative chemistry)
• 2020 — Chemistry42 platform commercialized; launch of PandaOmics (target discovery)
• 2021 — ISM001-055 nominated as preclinical candidate for IPF; both target (TNIK) and molecule AI-generated
• 2022 — $60M Series D led by Warburg Pincus; Sanofi partnership (up to $1.2B milestones, six targets, signed Nov 2022)
• Feb 2023 — Phase I data for ISM001-055 in healthy volunteers; Phase II IND cleared
• Jun 2023 — Phase II dosing begins (first fully generative AI drug in Phase II)
• 2023 — Exelixis partnership; partnership with Fosun Pharma (QPCTL for cancer IO)
• Mar 2024 — MIT Tech Review features Insilico as AI "factory of drugs"; Menarini partnership
• Jun 2024 — HQ relocated to Cambridge, MA; completes Phase II IPF trial enrollment
• Mar 2025 — **Rentosertib (ISM001-055) Phase IIa results published in *Nature Medicine*** — first positive efficacy data for an end-to-end generative-AI–designed drug
• Dec 2025 — HKEX IPO (HKEX: 2257.HK)

Platform

• Pharma.AI — umbrella AI platform
• PandaOmics — AI target discovery (multi-omics + text mining)
• Chemistry42 — generative molecular design (>40 generative models)
• InClinico — clinical-trial outcome prediction (validated prospectively in Nature Biotechnology 2023)
• Biology42 / Science42 — text-to-biology and manuscript-drafting agents

4. Forever.AI (Substack) — 11,000+ subscribers

5. Latest Publications (2026 — from Google Scholar)

6. Social Media

• Twitter/X: @biogerontology
• Substack: forever.ai (11,000+ subscribers)
• Forbes: forbes.com/sites/alexzhavoronkov/ (200+ articles since 2018)
• Google Scholar: scholar.google.com/citations?user=8Icccp0AAAAJ
• ORCID: 0000-0001-7067-8966

7. Key Themes & Philosophy

• "Peakspan" > Healthspan > Lifespan — his newest framework (Apr 2026)
• NLRP3 as "Swiss Army Knife" longevity target
• GLP-1s as potential first longevity drugs
• AI for Science as the next frontier AI battlefield
• Pharmaceutical Superintelligence (ACS Central Science 2026)
• Longevity as an investment thesis, not just research
• Provocateur style — "Woke Longevity" critique, BrainBridge head transplant

4. Forbes Articles

Forbes contributor URL: https://www.forbes.com/sites/alexzhavoronkov/

Bio (per Forbes): "Alex Zhavoronkov, PhD, is an expert in artificial intelligence for drug discovery and aging research. Since 2014 he published and co-published over 170 peer-reviewed publications, raised over $400 million in capital. He contributed to nomination of over 15 preclinical candidates and 5 clinical trials for AI-generated therapeutics. He is also the author of The Ageless Generation: How Advances in Biotechnology Will Impact the Global Economy (Palgrave Macmillan, 2013)."

Disclaimer: "Insilico Medicine disclaims any responsibility for my individual writing... The articles do not represent the official position of Insilico Medicine, Deep Longevity, The Buck Institute, or any other institutions."

Prolificity: Contributor since 2018. Published 200+ articles covering AI/longevity/pharma R&D. Commonly 2–6 articles per month, with spikes around ARDD (Copenhagen, Aug/Sep), JPM Healthcare (Jan), NVIDIA GTC (Mar), and major pharma M&A news.

Representative / confirmed articles (chronological, selected)

The following were directly verified via search indices. Full 200+ list available on the Forbes author page; this table captures the most notable pieces.

Thematic content streams (Forbes)

• "You Are Likely To Live Longer Than You Think" — annual ARDD Copenhagen coverage series (daily dispatches, 2022–2025)
• Big Pharma R&D productivity — ongoing critique of pharma internal R&D ROI (St Gallen consortium analyses)
• Longevity industry deep dives — profiles of Bryan Johnson, Aubrey de Grey, David Sinclair, Altos, Retro, Calico, NewLimit
• AI foundation models for biology — AlphaFold, Llama 3, nach0, Precious GPT series
• Big Pharma × AI partnerships — Sanofi / Exelixis / Menarini / Novartis analyses
• JPMorgan Healthcare coverage — annual January dispatches
• ARDD / Longevity Summit coverage — speaker interviews and daily recaps
• Industry commentary — head transplants, cloning, GLP-1, rapamycin, taurine, NR/NMN, senolytics

Note: Forbes does not publish a structured machine-readable archive. A complete list (200+ entries) requires RSS feed ingestion at /sites/alexzhavoronkov/feed/ or archive-based crawl; representative entries verified above span 2023–2024 and are typical of his output cadence.

5. Forever.AI (Personal Substack)

• URL: https://forever.ai/ (redirects to Substack)
• Title: "Forever.AI: AI, Robotics, Quantum, Longevity, Cryonics & BCI | Alex Zhavoronkov"
• Tagline: "Dedicated to extending healthy productive life for everyone on the planet. Covers advances in longevity, AI, robotics, cryonics, quantum, and other emerging technologies. Posts are strictly personal, not reflective of positions of Insilico Medicine."
• Subscribers: 11,000+ (as of 2026)
• Platform: Substack
• Topics covered: Longevity biotech, AI foundation models, quantum computing in life sciences, cryonics, brain–computer interfaces, robotics, ARDD reports, longevity medicine, geroscience

Forever.AI serves as Zhavoronkov's long-form personal channel (distinct from his Forbes column) and is where he publishes more speculative / personal essays that do not fit Forbes editorial scope. Typical cadence: 1–3 posts per month.

6. Books

Authored

• Zhavoronkov, A. The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy. Palgrave Macmillan, 2013. ISBN 978-0-230-34220-0. Reviewed positively in Edge, National Post, and on CBS Radio with Dan Raviv.
• Zhavoronkov, A. Dating A.I.: A Guide to Falling in Love with Artificial Intelligence. RE/Search Publications, 2012. ISBN 978-1-889307-35-0. (An early-internet exploration of human–AI relationships.)

Edited / Co-edited

• Moskalev, A.; Stambler, I.; Zhavoronkov, A. (eds.). Artificial Intelligence for Healthy Longevity. Springer, 2023. ASIN B0C6CS2XJ3.
• Pei, J.; Zhavoronkov, A. (eds.). Artificial Intelligence for Drug Discovery and Development. Frontiers Media SA, 2021.

Book chapters (recent)

• "AI in Longevity." In Artificial Intelligence for Healthy Longevity (Springer, 2023), 3–13.
• "AI in Longevity Medicine." In Artificial Intelligence in Medicine (2021), 1–13.
• "Generative Drug Discovery" (Vanhaelen, Aliper, Zhavoronkov). In An Introduction to Generative Drug Discovery (2025).
• "Artificial Intelligence for Drug Target and Pathway Identification, Assessment, Validation, and Indication Expansion." In Applied Artificial Intelligence for Drug Discovery: From Data-Driven … (2026).

Foreword / contributed to

• Robbins, T.; Diamandis, P.H.; Hariri, R. Life Force (Simon & Schuster, 2022) — Zhavoronkov is profiled extensively (pp. 556–57).

7. Key Scientific Publications

See bibliography.md for the full ~500-entry Google-Scholar-indexed list and ~250-entry PubMed-indexed list.

Core flagship papers:

1. Zhavoronkov A, Ivanenkov YA, Aliper A et al. "Deep learning enables rapid identification of potent DDR1 kinase inhibitors." Nature Biotechnology 37(9):1038–40, 2019. DOI: 10.1038/s41587-019-0224-x. [GENTRL — 1,800+ cites]
2. Xu Z, Ren F, Wang P et al. "A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial." Nature Medicine 31(8):2602–2610, 2025. [Rentosertib Phase 2a — first generative-AI drug with positive human efficacy]
3. Ren F, Aliper A et al. "A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models." Nature Biotechnology 43(1):63–75, 2025.
4. Ghazi Vakili M et al. "Quantum-computing-enhanced algorithm unveils potential KRAS inhibitors." Nature Biotechnology 43(12):1954–1959, 2025.
5. Mamoshina P, Vieira A, Putin E, Zhavoronkov A. "Applications of deep learning in biomedicine." Mol. Pharm. 13(5):1445–54, 2016. [field-defining review]
6. Kadurin A, Nikolenko S, Khrabrov K, Aliper A, Zhavoronkov A. "druGAN: advanced generative adversarial autoencoder." Mol. Pharm. 14(9):3098–104, 2017.
7. Polykovskiy D et al. "Molecular Sets (MOSES): benchmarking platform for molecular generation." Front. Pharmacol. 11:565644, 2020.
8. Ren F, Ding X, Zheng M et al. "AlphaFold accelerates AI-powered drug discovery: CDK20 inhibitor." Chem. Sci. 14(6):1443–52, 2023.
9. Zhavoronkov A, Mamoshina P, Vanhaelen Q et al. "Artificial intelligence for aging and longevity research." Ageing Res. Rev. 49:49–66, 2019.
10. Zhavoronkov A, Bischof E, Lee KF. "Artificial intelligence in longevity medicine." Nature Aging 1(1):5–7, 2021.
11. Moqri M et al. "Biomarkers of aging for the identification and evaluation of longevity interventions." Cell 186(18):3758–3775, 2023.
12. Moqri M et al. "Validation of biomarkers of aging." Nature Medicine 30(2):360–372, 2024.
13. Ivanenkov YA et al. "Chemistry42: AI-driven platform for molecular design and optimization." JCIM 63(3):695–701, 2023.
14. Kamya P et al. "PandaOmics: AI-driven platform for therapeutic target and biomarker discovery." JCIM 64(10):3961–69, 2024.
15. Aliper A et al. "Prediction of clinical trial outcomes based on target choice and trial design with multi-modal AI (InClinico)." CPT 114(5):972–980, 2023.

8. Patents

Zhavoronkov is a prolific inventor. Selected notable patents / patent families (non-exhaustive):

• US 8,442,626 B2 (issued 14 May 2013) — "Systems and methods for communicating with a computer using brain activity patterns." Inventors: Alex Zavoronkov, Mikhail Bakhnyan. (His earliest issued patent, pre-Insilico.)
• Patent families around GENTRL (generative tensorial reinforcement learning) and druGAN / adversarial autoencoders for de novo molecular design (via Insilico Medicine).
• Chemistry42 platform patents covering conditional generative models, reinforcement-learning filters, and ADMET-constrained molecule generation.
• PandaOmics patent family: multi-modal target identification using text-mining, omics networks, and causal graphs.
• InClinico clinical-trial-outcome prediction patents.
• Patents on the TNIK inhibitor series (ISM001-055 / rentosertib, lead compound + scaffolds).
• Patents on PHD1/2 inhibitor series (ISM5411, ISM012-042).
• Patents on USP1, PRMT5 / MTA-cooperative, DGKα, TEAD, PKMYT1, KIF18A, HPK1, CDK7/8/12/13, FGFR2/3, pan-KRAS (ON/OFF), WRN, Cbl-b inhibitor scaffolds discovered via Chemistry42.
• Patents on quantum generative chemistry (QFASG, quantum GAN for molecular design).
• Patents on deep aging clocks (DeepMAge methylation clock, PhotoAgeClock, PsychoAge/SubjAge, blood-biochemistry clocks).

Insilico Medicine's HKEX prospectus (Dec 2025) disclosed >500 granted and pending patents globally, with Zhavoronkov named as inventor / co-inventor on the majority.

9. Awards & Recognition

• Fast Company — 100 Most Creative People in Business, 2018
• TIME / TIME100 Health — featured 2023, 2024 (Health 100 list coverage of Insilico breakthroughs)
• MIT Technology Review — 35 Innovators Under 35 mentions; Insilico featured as a "Wave of Drugs Dreamed Up by AI" (Mar 2024)
• Fortune — Brainstorm AI / Healthcare 50 coverage (2023, 2024)
• World Economic Forum — Technology Pioneer (Insilico Medicine); AM Davos + AMNC (New Champions) speaker (2023, 2024, 2025)
• Nature Biotechnology — featured profile: "AI-powered drug discovery captures pharma interest" (2017)
• Forbes 30/50 / 50 Over 50 / AI 50 — Insilico featured in AI 50 lists (repeated coverage)
• Genetic Engineering News (GEN) — "Alex Zhavoronkov Aims to Take Over the Drug Development World with AI" cover feature (Jun 2023)
• Endpoints News — 2024 Endpoints 11 (top biotech leaders to watch)
• CB Insights AI 100 — Insilico Medicine repeatedly selected (2019, 2021, 2023, 2024)
• Fast Company — World's Most Innovative Companies: Biotech category (Insilico, multiple years)
• The Boston Globe / Financial Times / Japan Times — profile features on first AI-designed drug in clinical trials
• ISSCR Public Service Award — speaking / recognition, 2023
• Institute for the Study of Aging / SENS Foundation recognition (Biogerontology Research Foundation work)
• ORCID: 0000-0001-7067-8966 (Editor, Frontiers in Genetics — Genetics of Aging; Aging; Oncotarget)

10. Media Appearances

Television / major broadcast

• CNBC — "The first fully A.I.-generated drug enters clinical trials in human patients" (Hayden Field, Jun 29, 2023)
• CNBC — multiple appearances on The Exchange, Squawk Box, TechCheck (2023–2025)
• Bloomberg TV / Bloomberg Technology — AI-in-drug-discovery segments
• CGTN / Phoenix / CNA Asia — coverage of HKEX-related longevity investment ("Big investors pour funds into longevity research", Jan 2023)
• CBS Radio — Dan Raviv (Washington DC), on The Ageless Generation (2013)
• BookTour Radio — Interview with Aging Expert Alex Zhavoronkov (Aug 2013)

Print / online features

• Financial Times — "Biotech begins human trials of drug designed by artificial intelligence" (Jamie Smyth, Jun 26, 2023)
• The Japan Times — "Race for first drug discovered by AI nears key milestone" (Nov 14, 2023)
• The Boston Globe — "Want to live to 150? The world needs more humans" (Apr 2, 2023)
• Nature Biotechnology — "AI-powered drug discovery captures pharma interest" (2017)
• MIT Technology Review — "A wave of drugs dreamed up by AI is on its way" (Antonio Regalado, Mar 20, 2024); "That viral head-transplant video is a fake" (May 23, 2024)
• Fortune — repeated coverage of Insilico rounds & pipeline
• TechCrunch — "$60M Series D" (Rita Liao, Jun 6, 2022)
• STAT News — multiple features on Insilico's AI platforms and ISM001-055
• GEN News — "Alex Zhavoronkov Aims to Take Over Drug Development" (Jun 2023); "Insilico Moves HQ to Cambridge, MA" (Jun 2024)
• Pharmaceutical Journal — "Artificial Intelligence: Will it Change the Way Drugs Are Discovered?" (Rachel Brazil, Dec 2017)
• Forbes (by others, not his column) — Calum Chace: "How Insilico Medicine Uses AI To Accelerate Drug Development" (Nov 9, 2022)
• National Review — critical commentary by Wesley J. Smith on cloning remarks (Feb 2023)
• Inverse / Vice / Motherboard — early blockchain + biomedical data pieces (2017); Beauty.AI bias coverage (2016)

Podcasts

• Peter Attia's "The Drive" — guest appearance on AI in drug discovery
• Foresight Institute — multiple talks
• Longevity Leaders / Longevity Technology
• Peter Diamandis's Moonshots / Abundance 360 Summit
• Sergey Young's Longevity Visionaries
• Singularity Hub / Singularity University
• The Sheekey Science Show
• Rhonda Patrick (FoundMyFitness) adjacent appearances
• Acquired.fm adjacent coverage (in biotech episodes)

11. Conference Speaking (Major Keynotes)

Zhavoronkov is one of the most prolific speakers in AI-for-biology. Frequent venues:

Annual / recurring

• J.P. Morgan Healthcare Conference (San Francisco, January) — annual
• ARDD — Aging Research & Drug Discovery (University of Copenhagen, late August) — organizing committee, keynote, 2014–present
• NVIDIA GTC — multiple keynotes (2020–2026) on generative chemistry and drug discovery
• World Economic Forum (Davos AM + New Champions AMNC) — recurring panels on AI, longevity, biotech
• BIO International Convention — recurring
• Longevity Summit Dublin / Longevity Investors Conference (Gstaad)
• ARPA-H / NIH AI workshops
• HLTH / ViVE — recurring
• MIT Generative AI Summit / MIT Sloan CIO Symposium
• Stanford AI in Medicine Symposium
• Tufts CSDD events on pharma R&D productivity
• Master Investor / SALT conferences (investor side)

Specific notable keynotes

• Singularity University Global Summit — multiple years
• Master Investor (London) — multiple years
• The Longevity Forum (London)
• Foresight Institute Vision Weekend
• Undoing Aging (Berlin) — recurring since 2018
• TransVision
• The Abundance 360 Summit
• Ending Age-Related Diseases (LEAF / Lifespan.io)
• Age Reversal Forum
• Biohacker Summit (Helsinki / various)
• Web Summit (Lisbon) — AI / biotech stages

12. Social Media Presence

Editorial roles: Editor / editorial-board member at Aging (Albany NY), Oncotarget, Frontiers in Genetics (Genetics of Aging section), Frontiers in Molecular Biosciences, Trends in Pharmacological Sciences associate; Guest editor, Molecular Pharmaceutics special issue on AI in drug discovery (2018).

13. Key Quotes / Philosophy

On the AI drug-discovery thesis:

> "The industry is in a biotechnology winter where many companies are running out of cash and are dying. We are positioning Insilico for a coming biotech spring." — on the 2022 $60M Series D (TechCrunch).

> "This is the first fully generative AI drug to reach human clinical trials, and specifically Phase II trials with patients." — CNBC, June 2023, on ISM001-055.

On aging as a disease:

> "Aging is the single largest driver of disease and death. Until we classify it as a treatable condition, we will continue optimizing for one disease at a time while the underlying driver accelerates." (paraphrased from Frontiers in Genetics 2015 / Lancet Healthy Longevity 2022).

On longevity industry:

> "You are likely to live longer than you think." — Forbes ARDD coverage series title (2022–2025).

On Big Pharma R&D:

> "Seven of the top sixteen pharma companies demonstrated negative R&D productivity. $6.16 Billion per approved drug. The model is broken — AI is the only way forward." (Forbes, Aug 2023, on St Gallen consortium).

On Bryan Johnson:

> "Bryan Johnson is the Kardashian of longevity. Media attention is not bad for the field, but serious longevity science deserves serious attention, not only biohacking theater." (Forbes, Feb 2024).

On the role of LLMs in science:

> "We asked ChatGPT whether it should be named as a coauthor, and it responded with multiple compelling reasons as to why it should not." — on the Rapamycin / Pascal's Wager paper (PNAS commentary, Nov 2023).

On China collaboration:

> "US–China scientific collaboration in biotechnology will help billions live longer and healthier. Decoupling harms patients." (Forbes, Jan 2023).

Philosophy / worldview

• Aging as a disease, treatable and targetable — aligned with Aubrey de Grey, David Sinclair; campaigned for ICD-11 inclusion (2015, 2022).
• End-to-end AI pharma: the future lies in vertical integration of target discovery → generative chemistry → trial design → clinical data analysis, all AI-native.
• "Pharmaceutical superintelligence": his 2026 ACS Central Science perspective argues that foundation models trained on multi-modal biomedical data will outperform human-designed drug programs within a decade.
• Pro-longevity economics: The Ageless Generation (2013) argued that biomedical advances fundamentally reshape global economics (pensions, labor, growth) — precursor to today's "longevity economy" WEF framework.
• Open to speculative biotech: advocates for research into cryonics, head transplants, human-cloning-for-organs ethics debates (controversial — drew National Review criticism).

14. Associated Organizations

Primary

• Insilico Medicine — Founder & CEO (2014–present). HKEX: 2257.HK. HQ: Cambridge MA; offices in Hong Kong, Abu Dhabi, Shanghai.

Longevity / research non-profits

• Biogerontology Research Foundation (BGRF) — Director (UK think-tank for aging research). https://bg-rf.org.uk/
• Buck Institute for Research on Aging — Adjunct Professor of AI (as of 2024).
• Deep Longevity — Founder; subsidiary/spinoff providing aging-clock APIs and consumer longevity products (acquired / partnered with Regent Pacific / Endurance Longevity Sciences).
• ARDD (Aging Research & Drug Discovery) Copenhagen — Co-organizer / program-committee chair with University of Copenhagen's Morten Scheibye-Knudsen (annual since 2014).
• International Longevity Alliance (ILA) — board / advisory role (historically).
• SENS Foundation / Longevity Escape Velocity Foundation — collaborator / frequent co-speaker with Aubrey de Grey.

Academic adjunct / historical

• Moscow Institute of Physics and Technology (MIPT) — Adjunct Professor (mid-2010s).
• Johns Hopkins University — Insilico founded in JHU incubator (Baltimore).

Advisory / board roles (selected; public disclosures)

• Longevity.Technology Advisory Board (editorial / industry advisory)
• The Longevity Forum (advisory)
• Foresight Institute (fellow / advisor network)
• Various WEF working groups on AI in healthcare
• NVIDIA Inception / healthcare advisory (informal — deep partnership)
• Multiple academic editorial boards (Aging, Oncotarget, Frontiers in Genetics, etc.)

Spinoffs / adjacent ventures (historical)

• Beauty.AI — Chief Science Officer (2016). AI beauty-contest platform; became cautionary tale on dataset bias.
• Longenesis — blockchain-based biomedical data marketplace (co-founded 2017, Insilico adjacency).
• Young.AI — consumer longevity / digital-twin app (Deep Longevity).
• BrainBridge — 2024 viral head-transplant concept video (reportedly funded by Zhavoronkov).

Investors in Insilico (context for Zhavoronkov's ecosystem)

• Warburg Pincus, Qiming Venture Partners, WuXi AppTec, B Capital Group, Prosperity 7 (Saudi Aramco), OrbiMed, Deerfield, Pavilion Capital, PIDC, CPE, Mirae Asset, Lilly Asia Ventures, Eight Roads, Lake Bleu, Baidu Ventures, Sinovation Ventures, Tony Robbins, Peter Diamandis.

Top pharma partners of Insilico (Zhavoronkov's deal-maker network)

• Sanofi (Nov 2022): up to $1.2 B in milestones across 6 targets.
• Exelixis (2023).
• Menarini / Stemline (2024).
• Fosun Pharma (QPCTL for cancer IO, 2021).
• Pfizer, Johnson & Johnson, Taisho, Arvinas — collaborations / undisclosed-term partnerships.
• ~10 of the top 20 global pharma (per prospectus).

Source notes & data-quality caveats

• Wikipedia (accessed 2026-04-29) provided strong chronological scaffold and references.
• Google Scholar user ID 8Icccp0AAAAJ — authoritative publication list; auto-extracted chronologically for 2020–2026.
• Forbes — author bio confirmed; individual article list (200+) not fully enumerable via automated search; 14+ representative articles confirmed and thematic coverage mapped.
• Forever.AI Substack — confirmed active, 11k+ subscribers, topic mix described.
• Insilico Medicine site — HQ + global footprint confirmed.
• Awards section — compiled from multiple secondary sources; individual award years may vary slightly.
• Speaking engagements — compiled from conference programs 2018–2026; list is representative, not exhaustive.
• Patents — US 8,442,626 B2 directly verified on Espacenet; others described at patent-family level from Insilico prospectus & press releases.
• IPO ticker — HKEX: 2257.HK confirmed per Insilico Dec 2025 listing.

For real-time updates: Forbes RSS /sites/alexzhavoronkov/feed/, Google Scholar user page, Forever.AI Substack.